What is Aducanumab (Aduhelm)?

July 12, 2021

From the desk of guest author Joseph E. Gaugler, PhD, Professor and Robert L. Kane Endowed Chair in Long-Term Care and Aging, School of Public Health

Aducanumab Aduhelm, Laboratory

On June 7, 2021, the Food and Drug Administration (FDA) approved Aducanumab (Aduhelm), the first new drug for Alzheimer’s disease in almost 20 years. Aducanumab is a medication that may help slow the progression of early stage Alzheimer’s disease.

Many people living with dementia, families, and care professionals have questions regarding this news. We’ve compiled a set of frequently asked questions and some answers, to provide you with a better understanding of what to expect with the FDA approval of Aducanumab.

Read the Full Brief: Aducanumab FAQ

Learn more about Joseph E. Gaugler, PhD  

 

Joseph E Gaugler, PhD

About Dr. Gaugler: His research examines the sources and effectiveness of long-term care for persons with Alzheimer's disease and other chronic conditions. An applied gerontologist, Dr. Gaugler's interests include Alzheimer's disease and long-term care, the longitudinal ramifications of family care for persons with dementia and other chronic conditions, and the effectiveness of community-based and psychosocial services for older adults with dementia and their caregiving families.


Schedule a tour

Contact us

Quotes

Last evening, I spoke with Karen, the wife of Buzz, who passed away a couple days ago. She was so thankful for the short time that Buzz was at Emerald Crest. She said that the care both Buzz and the family were shown was excellent from everyone at EC. She was so thankful.  Among other things I remember her using the word ‘sincerity’ when talking about the words and actions of the staff. I thought that was a wonderful word to hear. That people showed genuine concern and care for everyone involved and that they felt confident, wanted and cared for.

— Rev. Arlen Solem, on behalf of Karen and Buzz

Quotes